title: Statins attenuate the development of atherosclerosis and endothelial dysfunction induced by exposure to urban particulate matter (PM10).
abstract: Exposure to ambient air particulate matter (particles less than 10μm or PM10) has been shown to be an independent risk factor for the development and progression of atherosclerosis. The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) have well-established anti-inflammatory properties. The aim of this study was to determine the impact of statins on the adverse functional and morphological changes in blood vessels induced by PM10. New Zealand White rabbits fed with a high fat diet were subjected to balloon injury to their abdominal aorta followed by PM10/saline exposure for 4weeks±lovastatin (5mg/kg/day) treatment. PM10 exposure accelerated balloon catheter induced plaque formation and increased intimal macrophages and lipid accumulation while lovastatin attenuated these changes and promoted smooth muscle cell recruitment into plaques. PM10 impaired vascular acetylcholine (Ach) responses and increased vasoconstriction induced by phenylephrine as assessed by wire myograph. Supplementation of nitric oxide improved the impaired Ach responses. PM10 increased the expression of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) in blood vessels and increased the plasma levels of endothelin-1 (ET-1). Incubation with specific inhibitors for iNOS, COX-2 or ET-1 in the myograph chambers significantly improved the impaired vascular function. Lovastatin decreased the expression of these mediators in atherosclerotic lesions and improved endothelial dysfunction. However, lovastatin was unable to reduce blood lipid levels to the baseline level in rabbits exposed to PM10. Taken together, statins protect against PM10-induced cardiovascular disease by reducing atherosclerosis and improving endothelial function via their anti-inflammatory properties.
authors.affiliation: UBC James Hogg Research Centre, St. Paul's Hospital, University of British Columbia, Vancouver, Canada.
authors.forename: Ryohei
authors.initials: R
authors.lastname: Miyata
authors.forename: Kunihiko
authors.initials: K
authors.lastname: Hiraiwa
authors.forename: Jui Chih
authors.initials: JC
authors.lastname: Cheng
authors.forename: Ni
authors.initials: N
authors.lastname: Bai
authors.forename: Renaud
authors.initials: R
authors.lastname: Vincent
authors.forename: Gordon A
authors.initials: GA
authors.lastname: Francis
authors.forename: Don D
authors.initials: DD
authors.lastname: Sin
authors.forename: Stephan F
authors.initials: SF
authors.lastname: Van Eeden
mesh_terms: D000818:Animals; D050197:Atherosclerosis / Q000209:etiology* / Q000517:prevention & control*; D001808:Blood Vessels / Q000473:pathology; D002791:Cholesterol, Dietary / Q000494:pharmacology; D051546:Cyclooxygenase 2 / Q000378:metabolism; D016207:Cytokines / Q000096:biosynthesis; D019332:Endothelin-1 / Q000378:metabolism; D016232:Endothelins / Q000097:blood; D004730:Endothelium, Vascular; D004781:Environmental Exposure / Q000009:adverse effects*; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D007150:Immunohistochemistry; D008055:Lipids / Q000097:blood; D008148:Lovastatin / Q000627:therapeutic use*; D008297:Male; D052247:Nitric Oxide Synthase Type II / Q000378:metabolism; D052638:Particulate Matter / Q000009:adverse effects*; D058226:Plaque, Atherosclerotic / Q000453:epidemiology / Q000473:pathology; D011817:Rabbits; D017382:Reactive Oxygen Species; D014504:Urban Health; D014652:Vascular Diseases / Q000209:etiology* / Q000517:prevention & control*
chemical_list: D002791:Cholesterol, Dietary; D016207:Cytokines; D019332:Endothelin-1; D016232:Endothelins; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D008055:Lipids; D052638:Particulate Matter; D017382:Reactive Oxygen Species; D008148:Lovastatin; D052247:Nitric Oxide Synthase Type II; D051546:Cyclooxygenase 2
keywords: Atherosclerosis; COX-2; DIT; NT; PM; PM(10); Particulate matter; Reactive oxygen species; SNP; Statins; diffuse intimal thickening; iNOS; nitrotyrosine; particulate matter; particulate matter less than 10μm; sodium nitroprusside; the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors